Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta’s medication intended for the treatment of Duchenne muscular dystrophy. This news prompted another significant decline in the price of Sarepta (NASDAQ: SRPT) shares. The EMA’s recommendation follows a slew of bad news for Sarepta investors, including patient deaths that resulted in sharp stock price declines, a securities class action (styled Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 1:25-cv-05317 (S.D.N.Y.)), a major company restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million, and the company’ agreement with the FDA to include a black box warning of acute liver injury and acute liver failure in Sarepta’s ELEVIDYS label. National shareholders rights firm Hagens Berman continues to investigate the lawsuit’s leg
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]CBS News
- Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]CBS News
- Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027Business Wire
- Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 8-K
- 12/18/25 - Form 4
- SRPT's page on the SEC website